First RSV vaccine approved in U.S. after decades of attempts – CBC

GSX’s Arexvy shot is targeted to older adults. It’s one several potential vaccines for respiratory virus

May 03, 2023

The U.S. approved the first vaccine for the respiratory syncytial virus (RSV) on Wednesday, shots to protect older adults against a respiratory virus that’s most notorious for attacking babies but endangers their grandparents, too.

The Food and Drug Administration decision makes GSK’s shot, called Arexvy, the first of several potential vaccines in the pipeline for RSV to be licensed anywhere.

The move sets the stage for adults 60 and older to get vaccinated this fall — but first, the Centers for Disease Control and Prevention must decide if every senior really needs RSV protection or only those considered at high risk from the respiratory syncytial virus. CDC’s advisers will debate that question in June.

After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.

Read more:

NationTalk Partners & Sponsors Learn More